Hillstar Bio

Transforming Autoimmune Treatment - Home

Business Model
B2B
Total Funding
$67.0M
Last Round
$67.0M Series AMar 2025
Rounds
1

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

About

Hillstar Bio is shaping a new era in autoimmune disease treatment through precision immunology. The company selectively targets and depletes pathogenic immune cells while sparing healthy ones, offering the potential for durable relief via an immune reset for patients with autoimmune conditions. Unlike traditional therapies that broadly suppress the immune system, its targeted approach addresses specific disease mechanisms by eliminating pathogenic cells and reducing the risks of chronic immunosuppression. Lead program HSB-101 depletes TRBV9+ T cells in axial spondyloarthritis and related HLA-B27-mediated conditions, with Phase 1 anticipated in 2026.

Summary

Hillstar Bio is a Biotech company. It has raised $67.0M in total across 1 round, most recently a $67.0M Series A round in Mar 2025. Investors include Novo Holdings A/S and Frazier Life Sciences.

Tech & App Stack

6 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Series ASeries AMar 2025
$67.0M

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Hillstar Bio on Indexed.vc
<a href="https://indexed.vc/companies/hillstar-bio"><img src="https://indexed.vc/api/badge/company/hillstar-bio" alt="Hillstar Bio on Indexed.vc" width="260" height="76" /></a>